Empirical drug sensitivity data will speed up the discovery and development of innovative cancer therapies in the biopharma pipeline, enhancing treatment efficacy while minimizing expensive side effects and cutting overall healthcare costs.

​

At EMPIRI, we’re driven to revolutionize cancer care through real-time, patient-specific drug response insights. By evaluating how individual tumor tissues respond to targeted cancer therapies, we’re connecting cutting-edge biopharma research directly to patient needs, optimizing the development of effective treatments.

 

Our practical, clinically proven strategy is designed to work across all cancer types, unbound by genomic profiles or histologic classifications.